{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:55:53Z","timestamp":1781672153262,"version":"3.54.5"},"reference-count":129,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed or refractory hematologic malignancies, achieving high response rates in B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and multiple myeloma. While the efficacy of CAR-T therapy is well established, quality of life (QoL) metrics have become increasingly important for guiding treatment decisions, patient counseling, and survivorship planning. Objectives: Most patients undergoing CAR-T therapy recover their initial QoL within 3 months, an improvement not typically seen with other treatment options. A comprehensive understanding of QoL is essential for delivering patient-centered care in the evolving CAR-T landscape. Conclusions: This review synthesizes current evidence on QoL outcomes in CAR-T recipients, including acute effects, recovery trajectories, comparisons with conventional therapies, and strategies to optimize QoL.<\/jats:p>","DOI":"10.3390\/hematolrep18030040","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T02:59:31Z","timestamp":1781146771000},"page":"40","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality of Life in CAR-T Cell Therapy"],"prefix":"10.3390","volume":"18","author":[{"given":"Caterina","family":"Alati","sequence":"first","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-4141","authenticated-orcid":false,"given":"Martina","family":"Pitea","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetana","family":"Porto","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Policastro","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2684-9269","authenticated-orcid":false,"given":"Erica","family":"Bilardi","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Utano","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Sgarlata","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1597-1913","authenticated-orcid":false,"given":"Ilaria Maria","family":"Delfino","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Idato","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Santoro","sequence":"additional","affiliation":[{"name":"Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Bio Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9400-5897","authenticated-orcid":false,"given":"Filippo Antonio","family":"Canale","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Naso","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/OP.21.00843","article-title":"Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!","volume":"18","author":"DuVall","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e70207","DOI":"10.1002\/hem3.70207","article-title":"Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up","volume":"9","author":"Thieblemont","year":"2025","journal-title":"Hemasphere"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"Boissel","year":"2024","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","article-title":"Immunotherapy in hematologic malignancies: Achievements, challenges and future prospects","volume":"8","author":"Tang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Yasui, H., Idogawa, M., Ishida, T., and Imai, K. (2025). Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders. Cells, 15.","DOI":"10.3390\/cells15010046"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Alati, C., Pitea, M., Molica, M., Scalise, L., Porto, G., Bilardi, E., Lazzaro, G., Mic\u00f2, M.C., Pugliese, M., and Canale, F.A. (2025). CAR-T Cell Therapies in B-Cell Acute Lymphoblastic Leukemia: Emerging Data and Open Issues. Cancers, 17.","DOI":"10.3390\/cancers17183027"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/17474086.2024.2357274","article-title":"Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: Are we ready for this?","volume":"17","author":"Martino","year":"2024","journal-title":"Expert Rev. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/14712598.2023.2292634","article-title":"Integrating CAR-T cell therapy into the management of DLBCL: What we are learning","volume":"23","author":"Martino","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Martino, M., Naso, V., Loteta, B., Canale, F.A., Pugliese, M., Alati, C., Musuraca, G., Nappi, D., Gaimari, A., and Nicolini, F. (2022). Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113332"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Martino, M., Canale, F.A., Alati, C., Vincelli, I.D., Moscato, T., Porto, G., Loteta, B., Naso, V., Mazza, M., and Nicolini, F. (2021). CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13112639"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Martino, M., Alati, C., Canale, F.A., Musuraca, G., Martinelli, G., and Cerchione, C. (2021). A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042150"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","article-title":"The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT","volume":"60","author":"Passweg","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy\u2014A Report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin. Hematol. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia","volume":"25","author":"Lu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/1078-0432.CCR-23-0568","article-title":"FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma","volume":"29","author":"Sharma","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2378543","DOI":"10.1080\/21645515.2024.2378543","article-title":"Approved CAR-T therapies have reproducible efficacy and safety in clinical practice","volume":"20","author":"Vera","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"AxicabtageneCiloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_22","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtageneciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"All ZUMA-7 Investigators and Contributing Kite Members. AxicabtageneCiloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"ZUMA-7 Investigators; Kite Members. Survival with AxicabtageneCiloleucel in Large B-Cell Lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtageneciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: A phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1182\/bloodadvances.2025018057","article-title":"Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma","volume":"10","author":"Charton","year":"2026","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1200\/JCO-25-00507","article-title":"Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients with Relapsed\/Refractory Large B-Cell Lymphoma","volume":"44","author":"Maziarz","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagenemaraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagenemaraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagenemaraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagenemaraleucel in follicular lymphoma: The phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in Patients with Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_35","first-page":"1302","article-title":"Brexucabtageneautoleucel for BTKi-naive relapsed\/refractory mantle cell lymphoma: Primary analysis of ZUMA-2 Cohort 3","volume":"147","author":"Kersten","year":"2025","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2147\/CMAR.S379807","article-title":"Clinical Insights on BrexucabtageneAutoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia","volume":"16","author":"Kopmar","year":"2024","journal-title":"Cancer Manag. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","article-title":"Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtageneautoleucel in ZUMA-3","volume":"39","author":"Shah","year":"2025","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.24.00321","article-title":"Outcomes After BrexucabtageneAutoleucel Administered as a Standard Therapy for Adults with Relapsed\/Refractory B-Cell ALL","volume":"43","author":"Roloff","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"IdecabtageneVicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1158\/1078-0432.CCR-24-4181","article-title":"FDA Approval Summary: IdecabtageneVicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma","volume":"31","author":"Sharma","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtageneautoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-Term (\u22655-Year) Remission and Survival After Treatment with CiltacabtageneAutoleucel in CARTITUDE-1 Patients with Relapsed\/Refractory Multiple Myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Dhakal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): An updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial","volume":"27","author":"Einsele","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1158\/1078-0432.CCR-16-3065","article-title":"Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity","volume":"23","author":"Anagnostou","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_50","first-page":"1121","article-title":"Clinical endpoints in oncology\u2014A primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40290-025-00568-9","article-title":"Association Between Health-Related Quality of Life Measures and Survival Endpoints in Oncology Clinical Trials and in Clinical Decision Making: A Narrative Review","volume":"39","author":"Valsecchi","year":"2025","journal-title":"Pharm. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12955-024-02312-4","article-title":"The use of patient-reported outcome measures to improve patient-related outcomes\u2014A systematic review","volume":"22","author":"Bonsel","year":"2024","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11136-025-04129-0","article-title":"Needs and health-related quality of life domains relevant to people in Europe with advanced cancer in need of palliative care: A systematic review of qualitative research","volume":"35","author":"Garin","year":"2026","journal-title":"Qual. Life Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jtct.2025.06.030","article-title":"Assessing Quality of Life and Symptoms in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT","volume":"31","author":"Banerjee","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_56","unstructured":"Webster, K., Cashy, J., and Cella, D. (2005). Measuring quality of life (QOL) in patients with non-Hodgkin\u2019s lymphoma (NHL): The Functional Assessment of Cancer Therapy\u2014Lymphoma (FACT-Lym). 12th Annual Conference of the International Society for Quality of Life Research, Springer."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jval.2012.08.2210","article-title":"Measuring health-related quality of life in leukemia: The Functional Assessment of Cancer Therapy\u2014Leukemia (FACT-Leu) questionnaire","volume":"15","author":"Cella","year":"2012","journal-title":"Value Health"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0959-8049(00)00447-0","article-title":"Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population","volume":"37","author":"Schwarz","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Pleyer, L., Heibl, S., Tinchon, C., Vallet, S., Schreder, M., Melchardt, T., Stute, N., F\u00f6hrenbach Quiroz, K.T., Leisch, M., and Egle, A. (2023). Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT. Cancers, 15.","DOI":"10.3390\/cancers15051388"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Bai, G., Zhang, J., Chen, Y., Cao, L., Yang, Y., and Jiang, C. (2024). Health-related quality of life assessed by EQ-5D-5L and its determinants among Chinese adults. Front. Public Health, 12.","DOI":"10.3389\/fpubh.2024.1383781"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1182\/blood-2025-6279","article-title":"Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: Results from a prospective observational study","volume":"146","author":"Efficace","year":"2025","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","article-title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: A global, single-arm, phase 2 trial","volume":"20","author":"Laetsch","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health-related quality of life with idecabtagenevicleucel in relapsed and refractory multiple myeloma","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: Comparison of idecabtagenevicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Han, M.W., Jeong, S.Y., Suh, C.H., Park, H., Guenette, J.P., Huang, R.Y., Kim, K.W., and Yoon, D.H. (2024). Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: Systematic review and meta-analysis. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1392831"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","article-title":"Effect of lisocabtagenemaraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma","volume":"5","author":"Patrick","year":"2021","journal-title":"Blood Adv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41409-025-02701-3","article-title":"Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations","volume":"60","author":"Greco","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtageneciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2017.06.014","article-title":"Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation","volume":"23","author":"Berro","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/bloodadvances.2024015599","article-title":"New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma","volume":"10","author":"Greenbaum","year":"2026","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1182\/bloodadvances.2025017081","article-title":"Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe","volume":"9","author":"Pennings","year":"2025","journal-title":"Blood Adv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s00277-026-06840-5","article-title":"Tisagenlecleucel yields superior patient-reported health-related quality of life compared to autologous stem cell transplantation in patients with relapsed\/refractory large B-cell lymphomas","volume":"105","author":"Obstfelder","year":"2026","journal-title":"Ann. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kazzi, C., Griffith, S.P., Ko, K.Y., Pearce, D.J., Parsons, S., Wesselingh, R., Seery, N., Tan, T.H., Wronski, M., and Rushen, T. (2026). Cognitive recovery following immune effector cell-associated neurotoxicity syndrome in the first 6 months after chimeric antigen receptor T-cell therapy. Transplant. Cell. Ther., Epub ahead of printing.","DOI":"10.1016\/j.jtct.2026.03.030"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e2021","DOI":"10.1002\/onco.13867","article-title":"Neurocognitive Impairment After Hematopoietic Stem Cell Transplant for Hematologic Malignancies: Phenotype and Mechanisms","volume":"26","author":"Harrison","year":"2021","journal-title":"Oncologist"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1182\/bloodadvances.2021006672","article-title":"Long-term patient-reported neurocognitive outcomes in adult survivors of hematopoietic cell transplant","volume":"6","author":"Wu","year":"2022","journal-title":"Blood Adv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jad.2021.02.041","article-title":"Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study","volume":"286","author":"Dai","year":"2021","journal-title":"J. Affect. Disord."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/sj.bmt.1702046","article-title":"The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation","volume":"24","author":"Hjermstad","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jtct.2022.05.004","article-title":"Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant","volume":"28","author":"Sidana","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/bloodadvances.2023012549","article-title":"Optimizing the post-CAR T monitoring period in recipients of axicabtageneciloleucel, tisagenlecleucel, and lisocabtagenemaraleucel","volume":"8","author":"Ahmed","year":"2024","journal-title":"Blood Adv."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/07347332.2025.2460060","article-title":"The patient and caregiver experience of CAR T-cell therapy: A qualitative analysis","volume":"43","author":"Reblin","year":"2025","journal-title":"J. Psychosoc. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdf031","article-title":"Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation","volume":"13","author":"Hensel","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_84","first-page":"e12454","article-title":"Help-seeking behaviour of patients with haematological malignancies treated with autologous stem cell transplantation","volume":"26","author":"Braamse","year":"2017","journal-title":"Eur. J. Cancer Care"},{"key":"ref_85","first-page":"249","article-title":"The long-term psychosocial effects of haematopoetic stem cell transplantation","volume":"12","author":"Gruber","year":"2003","journal-title":"Eur. J. Cancer Care"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Hansen, D.K., Liu, Y.H., Ranjan, S., Bhandari, H., Potluri, R., McFarland, L., De Braganca, K.C., and Huo, S. (2023). The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review. Cancers, 15.","DOI":"10.3390\/cancers15245746"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1007\/s12325-021-01839-y","article-title":"Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1182\/bloodadvances.2022008106","article-title":"Health-related quality of life with lisocabtagenemaraleucel vs standard of care in relapsed or refractory LBCL","volume":"6","author":"Abramson","year":"2022","journal-title":"Blood Adv."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jgo.2018.05.015","article-title":"Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant","volume":"10","author":"Rosko","year":"2019","journal-title":"J. Geriatr. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ejh.70037","article-title":"Role of Frailty in Assessing Eligibility for CAR T-Cell Therapy in Haematology","volume":"116","author":"Clesham","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"20406207241237594","DOI":"10.1177\/20406207241237594","article-title":"Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma","volume":"15","author":"Yuan","year":"2024","journal-title":"Ther. Adv. Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JOP.19.00335","article-title":"Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies","volume":"16","author":"Parrondo","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41409-025-02540-2","article-title":"Long-term patient-reported outcomes following allogeneic hematopoietic cell transplantation","volume":"60","author":"Beer","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"ref_94","first-page":"613.e1","article-title":"Quality of Life and Comorbidities of Long-Term Survivors of Allogeneic Hematopoietic Cell Transplant Versus Their Siblings","volume":"32","author":"Blosser","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/07347332.2020.1870644","article-title":"Predictors of quality of life in allogeneic hematopoietic stem cell transplantation survivors","volume":"39","author":"Brice","year":"2021","journal-title":"J. Psychosoc. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Balitsky, A., Pond, G.R., Davies, G.A., Fraser, G., Kouroukis, T., Levine, M., Meyer, R.M., and Foley, R. (2024). Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12574-2"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMe2118899","article-title":"CAR T-Cell Therapy for Large B-Cell Lymphoma\u2014Who, When, and How?","volume":"386","author":"Roschewski","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"335.e1","DOI":"10.1016\/j.jtct.2023.01.008","article-title":"Quality-Adjusted Time without Symptoms or Toxicity: Analysis of AxicabtageneCiloleucel versus Standard of Care in Patients with Relapsed\/Refractory Large B Cell Lymphoma","volume":"29","author":"Kersten","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-024-01579-w","article-title":"Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma","volume":"17","author":"Sesques","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/j.jval.2021.11.1165","article-title":"POSC340 Health-Related Quality of Life Among Refractory\/Relapsed B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated with KTE-X19: Phase 2 Results from Zuma-3 Trial","volume":"25","author":"Shah","year":"2022","journal-title":"Value Health"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/bloodadvances.2022009117","article-title":"Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"CiltacabtageneAutoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","article-title":"Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagenevicleucel or standard regimens: Patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial","volume":"11","author":"Delforge","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","article-title":"Health-related quality of life in patients given ciltacabtageneautoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b-2, open-label study","volume":"9","author":"Martin","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Habib, A., Ahmed, N., Khan, A.M., Chang, D., Paul, B., Shaikh, H., Strouse, C., Struble, E., Vegel, A., and Mahmoudjafari, Z. (2026). BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed\/Refractory Multiple Myeloma and Renal Impairment. Curr. Oncol., 33.","DOI":"10.3390\/curroncol33020080"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12967-025-07646-1","article-title":"Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: A review of recent advances","volume":"24","author":"Fatahichegeni","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtageneciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e085392","DOI":"10.1136\/bmjopen-2024-085392","article-title":"Protocol for a mixed-methods study to develop and feasibility test a digital system for the capture of patient-reported outcomes (PROs) in patients receiving chimeric antigen receptor T-cell (CAR-T) therapies (the PRO-CAR-T study)","volume":"14","author":"Hughes","year":"2024","journal-title":"BMJ Open"},{"key":"ref_110","first-page":"2401","article-title":"Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: Review and current progress","volume":"109","author":"Tchernonog","year":"2024","journal-title":"Haematologica"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1219.e1","DOI":"10.1016\/j.jtct.2024.09.013","article-title":"Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell Therapy","volume":"30","author":"Hoogland","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2020.04.027","article-title":"ECOG performance status \u22652 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data","volume":"145","author":"Maggio","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients\u2014A matched control multicenter cohort study","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtageneciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jtct.2020.10.022","article-title":"The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy","volume":"27","author":"Wudhikarn","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtct.2024.01.073","article-title":"Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model","volume":"30","author":"Nakamura","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"47","DOI":"10.46989\/001c.126463","article-title":"Prolonged Cytopenia with CAR-T Cell Therapy and Management Recommendations","volume":"7","author":"Dahunsi","year":"2025","journal-title":"Clin. Hematol. Int."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1002\/cncr.32961","article-title":"Importance of quality-of-life priorities and preferences surrounding treatment decision making in patients with cancer and oncology clinicians","volume":"126","author":"Williams","year":"2020","journal-title":"Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jtct.2023.06.012","article-title":"ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma","volume":"29","author":"Epperla","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-23-0228","article-title":"Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell-Engaging Cancer Therapies","volume":"5","author":"Kowalski","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Caimi, P.F., Pacheco Sanchez, G., Sharma, A., Otegbeye, F., Ahmed, N., Rojas, P., Patel, S., Kleinsorge Block, S., Schiavone, J., and Zamborsky, K. (2021). Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.745320"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtageneciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtageneciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_126","first-page":"180","article-title":"Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy","volume":"19","author":"Vinoo","year":"2025","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"ref_127","first-page":"393","article-title":"A point-of-care pilot randomized intervention to connect patients with cancer-induced financial toxicity to telehealth financial counseling","volume":"35","author":"Alacevich","year":"2024","journal-title":"Cancer Causes Control"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/hematology.2024000536","article-title":"Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies","volume":"2024","author":"Wang","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40264-025-01538-5","article-title":"Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients","volume":"48","author":"Renninger","year":"2025","journal-title":"Drug Saf."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/3\/40\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:32:29Z","timestamp":1781670749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/3\/40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":129,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["hematolrep18030040"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18030040","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}